- Conditions
- Hepatitis D, Hepatitis C, Hepatitis B, Liver Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 8,050 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1992
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Healthy Volunteer Hub
Healthy volunteer clinical trials in the U.S.
This page focuses on public ClinicalTrials.gov records that explicitly say they accept healthy volunteers. It starts with recruiting studies by default, and it does not guess the visitor's location. Add a city or state only when you want location-specific results before checking the official study record.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
5029
Shown on this page
12
Default status
Recruiting
The default view starts with recruiting studies because those are usually the most actionable.
Current order
Recently updated
Within the current status filter, results are ordered by the selected sort option.
Showing 433–444 of 5,029 healthy volunteer trials.
Live ClinicalTrials.gov results.
Live official records
- Conditions
- Blood Cancers, Blood Cancer, Leukemia, Lymphoma, Myeloma, Hematologic Cancer, Hematologic Malignancies, Hematologic Neoplasm, Hematologic Tumors
- Interventions
- Not listed
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Piscataway, New Jersey
- Conditions
- Diabetes (DM)
- Interventions
- Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution
- Drug
- Lead sponsor
- David D'Alessio, M.D.
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Depression
- Interventions
- Lung scan, Apremilast, 18F-PF-06445974
- Radiation · Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- Transcutaneous Auricular Vagus Nerve Stimulation, Sham Procedure (No Stimulation)
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Weight Loss
- Interventions
- Lifestyle, Lifestyle II
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy Volunteers, Alcohol Use Disorder (AUD)
- Interventions
- Placebo, Suvorexant
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- End Stage Renal Disease, Renal Impairment, Obesity, Overweight
- Interventions
- Ribupatide
- Drug
- Lead sponsor
- Kailera
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Orlando, Florida • San Antonio, Texas
- Conditions
- Fall, Mild Cognitive Impairment (MCI), Aging
- Interventions
- Digital STEADI-1, STEADI Standard of Care, Digital STEADI-2, Attentional control
- Behavioral
- Lead sponsor
- Friendi.fi Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- B-Cell Acute Lymphoblastic Leukaemia
- Interventions
- Not listed
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Jacksonville, Florida • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more
- Conditions
- Prognathism, Retrognathism, Dentofacial Deformities
- Interventions
- Not listed
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2046
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Surgery
- Interventions
- Trans-vaginal ultrasound
- Diagnostic Test
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas